Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd (ASX:NRT NASDAQ: NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

Dr Graham Kelly said: "The investment community has reacted positively in recent times to the Company's extensive drug discovery program and with significant growth in activity ahead in the short-term, we felt it was timely to appoint an advisory firm to build on that momentum and communicate our activities to the market to maximise shareholder value. Showcasing the Company to the wholesale investment community is a key part of our strategy to bring new investors into the stock through on-market buying. We look forward to working with the PCG team."

Jeff Ramson, Founder and CEO of PCG stated, "We are excited to work with the entire team at Novogen. We have extensive experience with Australian emerging growth companies that have stakeholders on several continents. We look forward to communicating the Novogen story to a larger group of US investors, who need to learn about their drug technology platforms and how management will execute the Company's strategy in the short and long term. We look forward to the partnership."

SOURCE Novogen Ltd